Changes of blood coagulation system during defibrinogenation therapy with batroxobin were investigated on 18 patients suffered from thrombo-embolic disorders (DVT, ASO, TAO, CAT, etc.).
Five patients were treated with Bothrops atrox marajoensis and the other 13 patients were treated with B. atrox moojeni. Batroxobin was given in doses of 0.6 to 2.3 PCU/kg as intravenous infusion for 2 to 4 hours. Nine out of 18 patients were treated with batroxobin and urokinase. On 7 out of the other 9 patients, surgical procedure was performed during defibrinogenation therapy.
Red blood cell, hematocrit, platelet counts and coagulation factors (II, V, VII-X, VIII, IX) were unchanged. Plasma fibrinogen concentration decreased to 133±46 mg/d
l in B. marajoensis treated patients, and to 55±28 mg/d
l in B. moojeni treated patients. Prothrombin time was prolonged at a fibrinogen level of below 100 mg/d
l. Platelet adhesion to glass and ADP induced platelet aggregation were not changed.
It was concluded from these results as follows:
1) Batroxobin from B. moojeni induced longer lasting defibrinogenation than B. marajoensis. And approximately 400 mg/d
l of fibrinogen could be broken down per 1 PCU/kg of B. moojeni.
2) Decreased fibrinogen concentration returned to normal limits 6 to 8 days after termination of the treatment.
3) Platelet function was not influenced by the decreased fibrinogen concentration.
4) No bleeding and thrombo-embolic complications were observed in all patients.
View full abstract